In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization

Publisher Website
Google Scholar
Abstract
In heart failure with reduced left ventricular ejection fraction (HFREF) patients, the dosage of sacubitril/valsartan is modulated according to a gradual increase regimen. Nevertheless, if patients exhibit tolerability problems, a provisional reduction of the dose of sacubitril/valsartan or even its interruption are recommended.